Dr. Kevin Pinski Presents Injectable Pearls at Noah

Key Takeaways

• Proper technique and patient expectations are critical to successful injectable outcomes
• Most complications are preventable with careful injection practices and aseptic technique
• Early recognition and management of adverse events can significantly improve patient outcomes

At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, patient selection, and complication management, offering a real-world perspective on optimizing outcomes while minimizing risk.

Dr. Pinski opened by emphasizing the importance of patient expectations, noting that injectables cannot achieve complete transformation with minimal product.

“We’re not going to convert the patient on your left into the patient on your right,” he said, referencing a multicenter study that demonstrated that full facial rejuvenation often requires multiple syringes—approximately 3 cc of hyaluronic acid filler for midface correction and up to 4 cc for lower face treatment.

Dr. Pinski advocated for incremental correction, spacing treatments over several weeks. This approach not only improves precision, he said, but also allows for more natural aesthetic changes that are less noticeable to others.

INJECTION STRATEGY AND TECHNIQUE

A structured injection approach was emphasized, typically proceeding from superior to inferior, lateral to medial, and deep to superficial planes. 

For patients new to fillers or requesting conservative treatment, Dr. Pinski highlighted the deep medial cheek fat pad as an optimal starting point. Treatment in this area, he said, can enhance anterior projection, soften nasolabial folds, and improve infraorbital hollowing, providing “a lot of bang for our buck.” 

Technique-related pearls included:
• Inject slowly and in small aliquots
• Avoid rapid, high-volume injections to reduce bruising and edema
• Recognize that adverse events are often technique-related

He also emphasized that precise anatomical knowledge is critical for fillers, whereas neuromodulators allow for slightly broader injection tolerance due to diffusion characteristics.

NEEDLES, CANNULAS, AND SAFETY CONSIDERATIONS

Dr. Pinski challenged the perception that cannulas are inherently safer than needles. He described this as “a false sense of security,” noting that intravascular injection can still occur with cannulas. 

Similarly, he questioned the reliability of aspiration prior to injection, pointing out that negative flashback does not exclude intravascular placement due to vessel collapse. 

In high-risk “danger zones,” he recommended more superficial injection planes to reduce vascular risk.

MANAGING ADVERSE EVENTS

While most complications are mild and self-limited, Dr. Pinski reviewed strategies for managing more persistent issues.

For prolonged bruising, he described the potential role of hemosiderin trapping within hyaluronic acid filler and noted that treatment with hyaluronidase and topical vitamin K may facilitate resolution. 

Infections, typically occurring 5 to 14 days post-procedure, are most commonly caused by staphylococcal or streptococcal organisms, he said. Prevention remains paramount, with emphasis on meticulous skin preparation and aseptic technique. 

Dr. Pinski also discussed biofilms. These low-grade bacterial colonies that may remain dormant and later reactivate, sometimes triggered by events such as dental procedures, can present as delayed granulomas months to years after injection and may respond to prolonged antibiotic therapy. 

VASCULAR COMPROMISE: RECOGNITION AND IMMEDIATE ACTION

Vascular occlusion remains one of the most serious complications of injectable procedures, and Dr. Pinski emphasized early recognition, including signs such as blanching and pain.

Immediate management, he said, includes:
• Stopping injection
• Massaging the area
• Applying warm compresses
• Administering nitroglycerin paste
• Injecting hyaluronidase

He highlighted that hyaluronidase can cross vessel walls and may be used aggressively when needed, noting that repeated dosing is acceptable in high-risk scenarios. 

Prompt intervention can prevent progression to necrosis, as illustrated in clinical cases presented during the session.

NEUROMODULATOR RESISTANCE AND TREATMENT FAILURE

Finally, Dr. Pinski addressed perceived treatment failures with neuromodulators, emphasizing that true immunologic resistance is rare, occurring in approximately 0.01% of patients. 

More commonly, suboptimal outcomes are related to technique, including improper injection placement or inadvertent intravascular delivery.

He also highlighted a less commonly discussed factor: prior immunization against botulinum toxin in military personnel, which may reduce treatment efficacy.